Post Cardiac Transplantation Lymphoproliferative Disorder Presenting as t(8;14) Burkitt Leukaemia/Lymphoma Treated With Low Intensity Chemotherapy and Rituximab

  1. Lookup NU author(s)
  2. Dr Kevin Windebank
  3. Dr Bridget Wilkins
Author(s)Windebank KP, Walwyn T, Kirk R, Parry G, Hasan A, Bown N, Wilkins B
Publication type Article
JournalPediatric Blood & Cancer
ISSN (print)1545-5009
ISSN (electronic)1545-5017
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
BackgroundPost-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL).ProcedureWe reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit.ResultsThere were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission.ConclusionsIn the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children.
PublisherJohn Wiley & Sons, Inc.
Actions    Link to this publication

Altmetrics provided by Altmetric